Clinical-stage pharmaceutical company's quarterly disclosure surfaces through Yahoo Finance's SEC filings tracker for ticker ENSC.
Ensysce Biosciences, Inc., the NASDAQ-listed clinical-stage pharmaceutical company trading under the ticker ENSC, filed a Form 10-Q with the U.S. Securities and Exchange Commission for the quarterly period ended March 31, 2026. The filing was submitted under commission file number 001-38306 and appears on the SEC's EDGAR archive, with the document also surfacing on Yahoo Finance's SEC filings page for the company. The filing represents a routine quarterly disclosure rather than a standalone news event, according to available records.
Ensysce Biosciences is based in the United States and focuses on developing prescription drugs aimed at severe pain relief while addressing risks tied to opioid misuse, abuse, and overdose. The company's SEC contact phone number is listed as (858) 263-4196 in the filing. As a clinical-stage company, Ensysce routinely discloses financial and operational updates through periodic SEC filings, including 10-Q and 10-K reports and 8-K notices of material events.
What The SEC Filing Confirms
The Form 10-Q filed by Ensysce Biosciences covers the three-month period ending March 31, 2026, consistent with a standard first-quarter reporting cycle. The SEC's own archive verifies the filing is authentic and tied to the company's registered securities. Market-tracking platforms, including MarketWatch, independently corroborate that the filing was submitted around May 15, 2026, for the period ended March 31, 2026, reinforcing that the document reflects a Q1 2026 report.
The Yahoo Finance page referenced in the original headline functions as an aggregator, surfacing SEC filings tied to the ENSC ticker rather than publishing original reporting. This is consistent with how Yahoo Finance typically labels its SEC filing pages, pairing the company ticker with the specific form type, such as 10-Q or 8-K. No separate narrative article accompanying the filing was identified in the available research.
Recent Filing Activity And Corporate Events
Beyond the 10-Q, Ensysce Biosciences has had additional SEC activity in 2026. The company filed an 8-K on May 15, 2026, alongside the quarterly report, a pairing that often accompanies earnings-related disclosures. More recently, the company filed both an 8-K and an amended 8-K/A on August 5 and August 6, 2026, respectively, each described as relating to corporate changes and voting matters. These filings are separate from the Q1 2026 10-Q and represent a distinct SEC event.
Third-party filing trackers, including StockTitan, MarketBeat, TradingView, and mlq.ai, show a consistent history of periodic disclosures from Ensysce Biosciences dating back through 2024, including prior 10-Q filings in May, August, and November of that year, along with annual 10-K reports. This pattern indicates the company maintains regular compliance with SEC reporting requirements typical of publicly traded clinical-stage pharmaceutical firms.
Financial Snapshot From Available Data
Separate financial data compiled by StockTitan, dated May 15, 2026, indicates Ensysce Biosciences reported revenue of $5.1 million for fiscal year 2025, a decline of 2.8% year-over-year. The same data shows a net loss of $10.2 million, narrowing by 27.4% compared to the prior year, and free cash flow of negative $7.9 million, with no comparable prior-year figure available. These figures are sourced from SEC filings data as of March 31, 2026, though the specific breakdown within the Q1 2026 10-Q itself, including management discussion and any risk disclosures, was not available in the supplied research.
Market data also shows Ensysce Biosciences shares trading at $0.43, down $0.09 or 17.24% as of a recent close, according to MarketBeat figures dated August 10, 2026. This price movement was noted alongside the company's SEC filings page but was not directly tied in the research to the Q1 2026 10-Q filing specifically, and may reflect broader market activity or other corporate developments, including the August 2026 8-K/A filings.
What Remains Unconfirmed
The detailed contents of the March 31, 2026 10-Q, including specific line items on cash position, research and development spending, clinical trial updates, or going-concern language, were not available in the supplied research. No executive quotes, official press releases, or earnings call commentary tied to the filing were identified. Additionally, it remains unclear whether the August 2026 8-K and 8-K/A filings on corporate changes and voting matters are connected in any way to the financial results disclosed in the earlier 10-Q.
Further reporting on the specific financial and operational details contained in the filing would require direct review of the SEC document text, available through the EDGAR archive, along with any related 8-K exhibits or press materials issued by Ensysce Biosciences.
